These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

82 related articles for article (PubMed ID: 10633033)

  • 1. Cyclin-dependent kinase inhibitors: useful targets in cell cycle regulation.
    Sielecki TM; Boylan JF; Benfield PA; Trainor GL
    J Med Chem; 2000 Jan; 43(1):1-18. PubMed ID: 10633033
    [No Abstract]   [Full Text] [Related]  

  • 2. Discovery of the antiviral activities of pharmacologic cyclin-dependent kinase inhibitors: from basic to applied science.
    Schang LM
    Expert Rev Anti Infect Ther; 2005 Apr; 3(2):145-9. PubMed ID: 15918771
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cyclin-dependent kinase inhibitors.
    Fischer PM; Endicott J; Meijer L
    Prog Cell Cycle Res; 2003; 5():235-48. PubMed ID: 14593718
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Silibinin upregulates the expression of cyclin-dependent kinase inhibitors and causes cell cycle arrest and apoptosis in human colon carcinoma HT-29 cells.
    Agarwal C; Singh RP; Dhanalakshmi S; Tyagi AK; Tecklenburg M; Sclafani RA; Agarwal R
    Oncogene; 2003 Nov; 22(51):8271-82. PubMed ID: 14614451
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cyclin-dependent kinase and protein kinase C inhibitors: a novel class of antineoplastic agents in clinical development.
    Kaubisch A; Schwartz GK
    Cancer J; 2000; 6(4):192-212. PubMed ID: 11038138
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Modulation of vascular smooth muscle cell growth by magnesium-role of mitogen-activated protein kinases.
    Touyz RM; Yao G
    J Cell Physiol; 2003 Dec; 197(3):326-35. PubMed ID: 14566962
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CDK inhibitors in cancer therapy: what is next?
    Malumbres M; Pevarello P; Barbacid M; Bischoff JR
    Trends Pharmacol Sci; 2008 Jan; 29(1):16-21. PubMed ID: 18054800
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cyclin-dependent kinase modulators: a novel class of cell cycle regulators for cancer therapy.
    Senderowicz AM
    Cancer Chemother Biol Response Modif; 2001; 19():165-88. PubMed ID: 11686013
    [TBL] [Abstract][Full Text] [Related]  

  • 9. p42/p44 MAPKs are intracellular targets of the CDK inhibitor purvalanol.
    Knockaert M; Lenormand P; Gray N; Schultz P; Pouysségur J; Meijer L
    Oncogene; 2002 Sep; 21(42):6413-24. PubMed ID: 12226745
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [G1 block of the cell cycle during differentiation of F9 cells correlates with accumulation of inhibitors of the activity of cyclin-kinase complexes of proteins p21/Waf1 and p27/Kip].
    Malashicheva AB; Kisliakova TV; Pospelov VA
    Tsitologiia; 2002; 44(7):649-55. PubMed ID: 12455373
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cdk pathway: cyclin-dependent kinases and cyclin-dependent kinase inhibitors.
    Gitig DM; Koff A
    Methods Mol Biol; 2000; 142():109-23. PubMed ID: 10806617
    [No Abstract]   [Full Text] [Related]  

  • 12. p18(INK4c) collaborates with other CDK-inhibitory proteins in the regenerating liver.
    Luedde T; Rodriguez ME; Tacke F; Xiong Y; Brenner DA; Trautwein C
    Hepatology; 2003 Apr; 37(4):833-41. PubMed ID: 12668976
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 3-Acyl-2,6-diaminopyridines as cyclin-dependent kinase inhibitors: synthesis and biological evaluation.
    Lin R; Lu Y; Wetter SK; Connolly PJ; Turchi IJ; Murray WV; Emanuel SL; Gruninger RH; Fuentes-Pesquera AR; Adams M; Pandey N; Moreno-Mazza S; Middleton SA; Jolliffe LK
    Bioorg Med Chem Lett; 2005 May; 15(9):2221-4. PubMed ID: 15837297
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Re: preclinical and clinical development of cyclin-dependent kinase modulators.
    Darzynkiewicz Z
    J Natl Cancer Inst; 2000 Jul; 92(14):1184-5. PubMed ID: 10904096
    [No Abstract]   [Full Text] [Related]  

  • 15. Small-molecule inhibitors of the cell cycle.
    Crews CM; Mohan R
    Curr Opin Chem Biol; 2000 Feb; 4(1):47-53. PubMed ID: 10679374
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cell cycle-associated kinases as targets for therapy in lung cancer.
    Camidge DR
    J Thorac Oncol; 2010 Dec; 5(12 Suppl 6):S461-2. PubMed ID: 21102239
    [No Abstract]   [Full Text] [Related]  

  • 17. Cyclin-dependent kinases as targets for cancer therapy.
    Shah MA; Schwartz GK
    Cancer Chemother Biol Response Modif; 2005; 22():135-62. PubMed ID: 16110611
    [No Abstract]   [Full Text] [Related]  

  • 18. Chemical inhibitors: a tool for plant cell cycle studies.
    Planchais S; Glab N; Inzé D; Bergounioux C
    FEBS Lett; 2000 Jun; 476(1-2):78-83. PubMed ID: 10878255
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cell cycle regulatory kinase modulators: interim progress and issues.
    Sausville EA
    Curr Top Med Chem; 2005; 5(12):1109-17. PubMed ID: 16248786
    [TBL] [Abstract][Full Text] [Related]  

  • 20. New combination therapies with cell-cycle agents.
    Deep G; Agarwal R
    Curr Opin Investig Drugs; 2008 Jun; 9(6):591-604. PubMed ID: 18516759
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.